Skip to content
Precision for Medicine
Meeting on the Mesa-Header image_Resized

Monday, October 5 - Wednesday, October 7, 2026

Cell & Gene Meeting on the Mesa 2026

Meet Precision Experts in Phoenix

 

Precision for Medicine is excited to attend Cell & Gene Meeting on the Mesa 2026, one of the industry's leading forums for advancing the future of cell and gene therapies.

As development programs move from discovery to clinical execution, sponsors face increasing pressure to generate robust data, navigate evolving regulatory expectations, and prepare for scale. Precision brings together clinical development, specialty laboratory, biomarker, and regulatory expertise to help address these challenges through a fully integrated approach.

Meet with our team to discuss your development strategy, explore solutions for your program, and learn how Precision helps sponsors move advanced therapies forward more efficiently.

Complete the form below to schedule dedicated time with our team in Phoenix.

 

Don't Miss Precision's Presentation at Meeting on the Mesa

Join Precision for Medicine's clinical development leaders as they explore the operational and regulatory considerations shaping today's advanced therapy programs. This session will provide practical insights into navigating complexity across development, generating high-quality data, and advancing cell and gene therapies with confidence.

 

Meet our team! 

Contact us using the form below. Our team will reach out and set up a meeting time at Meeting on the Mesa 2026.

Curated insights from the frontlines of cell & gene therapy research

 

Read: Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

Clinical Trials - Oncology - Cell Therapies

Case Study: Conducting Autologous Cell Therapy Research Across 3 Continents with Zero Sample Loss

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1785476963368, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover
Read: Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

Translational Research

Developing a Comprehensive Strategy for Implementing AI & Multi-Omics for Translational Research

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=199448088864, hs_child_table_id=0, hs_updated_at=1762810484868, hs_published_at=1785476963368, avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Kaylee%20Mueller.png',altText='Kaylee Mueller',fileId=199456336149}, lastname=Mueller, hs_initial_published_at=1762810487482, hs_created_by_user_id=26433386, hs_created_at=1762810467146, hs_is_edited=false, hs_deleted_at=0, name=Kaylee, slug=kaylee-mueller, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Kaylee Mueller avatar

    Kaylee Mueller

Discover
Read: Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

Early Phase Research - Gene Therapies

Case Study: Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1785476963368, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White

Discover

Meeting on the Mesa 2026

2400 E Missouri Ave, Phoenix, AZ 85016